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Asthma and allergic diseases are common among children and adolescents worldwide.1 
Approximately 6-8% of Swedish and Danish children have asthma, and rhinitis or atopic 
dermatitis are even more common.1, 2 Although the previous increase in asthma prevalence 
seems to have reached a plateau, variation in prevalence between genetically similar 
populations strongly implies that a substantial proportion is attributable to environmental 
aspects.3  
In order to study causes and consequences of asthma and allergic disease, it is of great 
importance to have valid measures of exposures, outcomes and confounders and adequate 
sample sizes. Many prospective birth cohorts, case-control studies and randomized control 
trials have ascertained feasible associations from data collected through questionnaires and 
clinical examinations. In some countries, these have been complemented with population-
based information from medical records collected at antenatal clinics and hospital visits, and 
to prescribed drugs; all linked through personal identity numbers. Importantly, asthma 
outcomes have been well ascertained in validation studies through extensive linkages, medical 
record reviews and algorithms.4, 5 These register-based total population studies also allow 
comparison on asthma prevalence and incidence between different countries.  
In a recent study by Henriksen et al, incidence rates of atopic dermatitis, asthma and allergic 
rhinoconjunctivitis in the Danish and Swedish child populations are reported based on data 
from national registers.6 Incidence rates were ascertained through algorithms based on 
disease-specific dispensed prescribed medication and/or specific hospital contacts. Findings 
were that incidence rate of atopic dermatitis was stable and allergic rhinoconjunctivitis 
decreased in both countries, whereas the incidence rate of asthma increased until 2006 and 
stabilized for the rest of the study period in Denmark and increased in Sweden. They also 
report that at age 5 years, one third of all children were affected with at least one of the 
conditions.  
The study certainly shows that it is possible to assess patterns in prevalence and incidence of 
asthma and allergic disease through the population-based registers, but a few issues remain to 
acknowledge and discuss.  
Firstly, coverage of diagnoses in the Patient Registers (International Classification of 
Diseases, 10th revision, ICD-10) and medication in the Prescribed Drug Registers (Anatomical 
Therapeutic Chemical, ATC classifications system) is of great importance. The authors have 
made a great effort to identify algorithms for definition of atopic dermatitis, asthma and 
allergic rhinoconjunctivitis. Although the algorithms are fairly including it seems feasible that 
they have conditioned at least two filled prescriptions of “corticosteroids for topical use” 
(ATC-code D07) for atopic dermatitis and at least two prescriptions for “inhaled 
corticosteroids for rhinitis” (ATC-code R01AD) or “antihistamines for systemic use” (ATC-
code R06A) for allergic rhinoconjunctivitis. When it comes to asthma controller medication, 
the frequency of distributions and selection of included medications becomes particularly 
important. The Swedish Patient register covers all hospital visits and approximately 75-80% 
of outpatient visits to specialists but not those to primary health care. This is why dispensed 
medication from the Prescribed Drug Registers, which covers all health care facilities, is such 
an important source. In a recent validation study of asthma and atopic dermatitis, we 
concluded that asthma medication (≥ two filled prescriptions) is a suitable proxy for asthma 
with a positive predicted value (PPV) by predefined medication criteria that ranged between 
0.75 and 0.94 depending on age group. Meanwhile, medications for atopic dermatitis had a 
much lower PPV.4 We based our validation on a large number of medical records which 
would be a great addition also for this study, but in the meantime we are very satisfied with 
the opportunity to have alternative measures of atopic dermatitis. Another concern is that 
many of the drugs to treat atopic dermatitis and rhinoconjunctivitis can be provided over the 
counter (OTC) in Swedish pharmacies since 1992 and in supermarkets since 2009. Thus, 
incidence and prevalence of these diseases based on the Prescribed Drug Registers will be 
underestimated. Also, the authors have assessed rhinoconjunctivitis from birth, whereas it is 
more common that the disease starts later in preschool age. Hence, while it is a clear 
advantage to have alternative measures of asthma and allergic disease, ideally OTC sales 
should be considered when interpreting incidence trends. An increase in the proportion of 
OTC sales can otherwise be misinterpreted as a decrease in incidence rates.  
Secondly, it is worth noting that the study populations were born during different time 
periods; in Denmark 1998-2011 and in Sweden 2006-2010. Thus, the Danish data covers both 
preschoolers and school-age children from 2006 and onwards, while the Swedish shows the 
incidence rate ratios (IRR) for infants only (< 1 year) in 2007 and the IRR for 2010 represents 
0-3 year olds. The Cox model ensures that each IRR is adjusted for age, but it cannot make up 
for such changes in the age composition over time. Since the diseases have different 
phenotypes in preschoolers and school age children and incidence differs with age, variations 
in age composition over time and between the countries may make overall comparisons 
difficult. It is worth noting that in the first few years of Danish data, where the same age 
groups are present as in the Swedish data, the incidence increase is similar, with 30%  
increase for asthma from 1998-2002 (Figure 1: ~0.85/0.65=1.31), as compared to 25% 
(Figure 1: IRR≈1.25) increase 2006-2010 in Sweden. During the same periods the incidence 
in atopic eczema is stable in both countries, while there is a markedly larger decrease in 
allergic rhinoconjunctivitis in Sweden (38%, Figure 1: IRR≈0.62) than in Denmark (11%, 
Figure 1: ~1.05/1.18). This can also be seen by comparing the shapes of the Swedish curves 
for 2006-2010 with those of the Danish curves for 1998-2002 in Figure 1. Comparing similar 
countries as is done in this study can improve our understanding of the diseases and the 
interpretation of the data. However, age stratified incidence rate ratio curves would be of great 
help for further understanding of the incidence development in the two countries. 
Finally, the authors claim there has been an increase in asthma incidence in Sweden over 
time, illustrated with a red line in their Figure 1. The increase seems to have been there only 
between 2009 and 2010, and since the incidence is not calculated for later years it is difficult 
to claim an overall increase. Interestingly, the increase coincides with the swine flu pandemic 
when Swedish residents were invited to immunize their little children.7 Also, public health 
information and surveillance was targeted towards infants and young children whose parents 
were advised to contact health care in case of respiratory symptoms related to influenza. We 
also know that the number of health care events and prescribed medication increased during 
this year which may reflect the increase in asthma diagnoses and medication. In Denmark, 
immunization was primarily targeted towards risk groups8 and children in the Danish study 
population were older at the time of the influenza pandemic, possibly explaining why there is 
not a similar rise in asthma incidence during those years. 
In conclusion, the study is of great interest and illustrates that despite some differences in 
population characteristics the incidence rates are fairly similar between the two countries. The 
results reinforce the possibilities to study causes and consequences of these diseases in 
population-based register linkages. In doing so, sophisticated research methods including 
family design such as sibling comparison can rule out alternative mechanisms that confound 
associations between early risks and later disease, including all unmeasured genetic and 
environmental factors shared by siblings such as we have recently shown for antibiotics9 and 
parental age.10 Some of the authors of this paper also have expertise in twin design, which 
enables a particularly interesting sibling comparison. Most importantly, this article highlights 
the importance of using valid measures in register-based research and calls for advanced 
epidemiological analyses methods now and in the future.  
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